Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy.

ABSTRACT:

Purpose

Curative intended treatment is challenging in patients with relapsed or refractory acute myeloid leukemia (r/r AML) and associated with a dismal prognosis for long-term survival. Despite novel treatment options, the majority of patients are treated with chemotherapy-based regimens. Although widely used, little data exist on the combination of fludarabine, cytarabine, granulocyte colony stimulating factor (FLAG) and mitoxantrone as salvage strategy for r/r AML.

Materials and methods

Sixty-six patients receiving Mito-FLAG for r/r AML treated at a German tertiary care center between 2009 and 2019 were analyzed with regard to response rates, survival and safety profile.

Results

Overall response rate was 75.8% with 56.1% of patients achieving complete remission (CR

SUBMITTER: Muhleck R 

PROVIDER: S-EPMC9349069 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature